立体定向体部放疗与肝切除治疗复发性小肝癌:两项随机试验的倾向性评分校正事后分析
本研究基于两项随机试验的事后分析,纳入158例单发复发性小肝癌(≤5 cm)患者,比较SBRT(83例)与肝切除(75例)的疗效。主要终点局部无进展生存(LPFS)在两组间无显著差异,3年LPFS率分别为84.3%和76.8%(HR 0.70,P=0.311);总生存、无进展生存及不良事件发生率亦无显著差异。结论认为SBRT肿瘤控制与长期结局与切除相当,可作为复发性小肝癌的潜在替代选择。
要点
- 复发性小肝癌SBRT与切除的3年LPFS率分别为84.3%和76.8%,差异无统计学意义。
- 两组中位PFS、3年OS及不良事件发生率均无显著差异。
- 校正混杂因素后比较结果一致,SBRT可作为切除的潜在替代方案。
核心结论
- SBRT对复发性小肝癌提供满意的肿瘤控制和长期结局,与肝切除相当。
- SBRT可能成为复发性小肝癌肝切除的潜在替代选择。
研究设计与样本
- 基于两项随机对照试验(NCT01833286 切除;NCT04047173 SBRT)的事后分析,采用倾向性评分校正。
- 纳入单发复发性肝细胞癌且肿瘤≤5 cm的患者,共158例,SBRT组83例、切除组75例。
- 主要终点为局部无进展生存(LPFS)。
主要发现
- 3年LPFS率:SBRT组84.3%(95% CI 76.1-92.5),切除组76.8%(95% CI 67.2-86.4),HR 0.70(95% CI 0.35-1.40),P=0.311。
- 中位无进展生存期:SBRT组37.6个月(95% CI 26.0-49.2),切除组26.3个月(95% CI 18.8-33.8),HR 0.80(95% CI 0.53-1.21),P=0.287。
- 3年总生存率:SBRT组90.3%(95% CI 83.4-97.2),切除组81.1%(95% CI 76.5-90.1),HR 0.53(95% CI 0.23-1.20),P=0.118。
- 不良事件发生率两组相似(P=0.695)。
- 校正混杂变量后比较结果保持一致。
临床怎么用
- 对于单发≤5 cm的复发性小肝癌,SBRT可作为肝切除的替代方案进行个体化选择。
- SBRT在局部控制、生存及安全性方面与切除相当,可考虑用于不宜手术或偏好无创治疗的患者。
局限性
- 为两项随机试验的事后分析,非直接头对头随机比较,尽管采用倾向性评分校正仍可能存在残余混杂。
- 样本量有限(共158例),事件数较少,置信区间较宽,统计效能可能不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic body radiotherapy (SBRT) has been proven effective for treating small hepatocellular carcinoma (sHCC); however, the comparative efficacy of SBRT and surgical resection remains unknown. This analysis aims to compare the outcomes of SBRT and resection in treating recurrent sHCC. METHODS: Two randomized controlled trials enrolled recurrent sHCC undergoing resection (NCT01833286) or SBRT (NCT04047173). Patients with single recurrent HCC ≤ 5 cm were included in this study. The primary endpoint was local progression-free survival (LPFS). RESULTS: A total of 158 patients were included, with 83 and 75 patients assigned to the SBRT and resection cohorts, respectively. The cumulative 3-year LPFS rates were 84.3% (95% CI, 76.1-92.5) with SBRT and 76.8% (95% CI, 67.2-86.4) with resection, respectively (HR, 0.70 [95% CI, 0.35-1.40]; P = 0.311). The median progression-free survival time of the SBRT and resection group was 37.6 (95% CI, 26.0-49.2) and 26.3 (95% CI, 18.8-33.8) months, respectively, with no significant differences (HR, 0.80 [95% CI, 0.53-1.21]; P = 0.287). The 3-year overall survival rates were 90.3% (95% CI, 83.4-97.2) in the SBRT group, and 81.1% (95% CI, 76.5-90.1) in the resection group (HR, 0.53 [95% CI, 0.23-1.20]; P = 0.118). The comparison results remained consistent after adjusting for confounding variables. The incidences of adverse events were similar between the two groups (P = 0.695). CONCLUSIONS: SBRT provides satisfactory tumor control and long-term outcomes, comparable to those of resection. SBRT could be a potential alternative to resection in recurrent sHCC.
引用
- Fu Y, Liu S, Chen J, et al. Stereotactic body radiotherapy versus hepatic resection for recurrent small hepatocellular carcinoma: A post-hoc analysis with propensity score adjustment from two randomized trials. Eur J Cancer. 2026. PMID: 41833569. doi:10.1016/j.ejca.2026.116675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。